{
    "nct_id": "NCT06490328",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2024-07-08",
    "study_start_date": "2024-05-30",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: DKF-MA102"
            }
        ]
    },
    "long_title": "A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer",
    "last_updated": "2024-07-08",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "Choung-Soo Kim, M.D.,Ph.D",
    "principal_investigator_institution": "Ewha Womans University Mokdong Hospital",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 154,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "1. Adult male aged 19 or older",
        "2. Histologically or cytologically-confirmed prostate cancer",
        "3. Serum testosterone level \\>150 ng/dL",
        "4. ECOG PS grade \u2264 2",
        "5. Life expectancy of at least 1 year",
        "Exclude - Exclusion Criteria:",
        "Exclude - 1. History of surgical procedures such as testicular resection, adrenal resection, and pituitary resection",
        "Exclude - 2. History of hormone therapy",
        "Exclude - 3. History of 5\u03b1-reductase inhibitor",
        "Exclude - 4. History of radical radiation therapy",
        "Exclude - 5. History of adjuvant male hormone block therapy",
        "Exclude - 6. Severe liver failure",
        "Exclude - 7. Serum creatinine \u22651.5 times the ULN",
        "Exclude - 8. Hormone-independent prostate cancer",
        "Exclude - 9. Diagnosed pituitary adenoma",
        "Exclude - 10. Brain metastasis or spinal cord compression",
        "Exclude - 11. Requires prostatectomy, radiation therapy, chemotherapy, and anti-androgen therapy during the clinical trial period",
        "Exclude - 12. Urinary tract obstruction",
        "Exclude - 13. Cardiovascular disease",
        "Exclude - 14. Significant impairments in the digestive system, respiratory system, endocrine system, and central nervous system",
        "Exclude - 15. Uncontrolled diabetes",
        "Exclude - 16. Allergic reaction or hypersensitivity to any ingredient of the investigational product or to a synthetic GnRH or GnRH analogs",
        "Exclude - 17. Severe asthma, severe vascular edema, and severe hives",
        "Exclude - 18. Significant infection",
        "Exclude - 19. Lack of self-determination due to psychiatric illness",
        "Exclude - 20. Participating in another interventional clinical trial",
        "Exclude - 21. Pregnant or unwilling to use medically approved contraception",
        "Exclude - 22. Deemed inappropriate to participate in this clinical trial by the investigator"
    ],
    "short_title": "Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Dongkook Pharmaceutical Co., Ltd.",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "DKF-MA102",
                        "arm_internal_id": 0,
                        "arm_description": "Leuprorelin acetate",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: DKF-MA102",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "clinical": {
                            "age_numerical": ">=19",
                            "gender": "Male",
                            "disease_status": [
                                "Metastatic"
                            ],
                            "oncotree_primary_diagnosis": "Prostate Adenocarcinoma"
                        }
                    }
                ]
            }
        ]
    }
}